Neuralink Ethical Concerns: What You Need to Know in 2026

• Neuralink's animal research is subject to Institutional Animal Care and Use Committee (IACUC) oversight, and its past testing drew federal scrutiny.
• Human trials depend on informed consent, which is harder to get right for people with paralysis or speech loss.
• Neuralink's privacy policy says trial data is governed by trial protocols and consent forms, and the proposed MIND Act would direct the FTC to study neural data.

Animal testing and oversight

Neuralink tested its implant in animals for years before the first person received one, and that testing is where most of the criticism began. Reports in 2022 described complications in monkey testing, and an FDA inspection of Neuralink's own California animal lab in June 2023 found record-keeping and quality-control problems, as Reuters reported in early 2024. The FDA said the findings called for voluntary fixes rather than regulatory action.

Animal research in the United States must be reviewed by an Institutional Animal Care and Use Committee, which oversees pain control, veterinary care, and the number of animals used. Critics argue that such testing is still needed before results like thought-controlled cursors can reach people.

Informed consent in human trials

Human trials began in January 2024 with participants who have paralysis or, in the VOICE trial, severe speech loss. Consent has to cover risks, benefits, and alternatives in a form the participant can follow, and each trial site's protocol is reviewed by an ethics board. Participants can withdraw from a study.

The first UK participant received his implant in October 2025, and the Canadian trial at Toronto's University Health Network performed its first two implants in late August and early September 2025. Patients report restored independence, such as doing 3D design by thought. The VOICE speech trial implanted its first participants in early 2026.

Brain data privacy

Neural data, the raw signals from 1,024 electrodes, has started debates about mental privacy and the risk of hacking or misuse. Neuralink's privacy policy says the company does not sell personal information, and that data from clinical trials is governed by the trial protocol and each participant's informed consent. The implant sends its signals over Bluetooth to the participant's paired device.

On September 24, 2025, Senators Schumer, Cantwell, and Markey introduced the MIND Act, which would direct the FTC to study how neural data is collected and used and recommend protections. Colorado and other states have extended their privacy laws to cover neural data. Neuralink submitted results from its first three participants to the New England Journal of Medicine; the paper had not been published as of October 2026.

Implant safety and long-term risks

Many of the first participant's threads retracted in 2024. After changes made following Noland's surgery, Neuralink reported higher signal quality in 18 of the next 20 participants and says it is still improving thread retention. In January 2026, it reported zero serious device-related adverse events, according to its two-year update.

Neuralink's roadmap called for about 3,000 channels in 2026, and a 3,000-channel implant was disclosed in September 2026. Blindsight, the planned vision implant, has not started human trials. Concerns about who will be able to afford the implant once it is approved remain open.

This article was first published in October 2025 and corrected in October 2026; the latest patient count is on the patient table.